Novo Nordisk (NVO) stock in focus as company decides to cut 2025 bonuses for employees in Denmark amid cost-cutting measures ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...